Bristol-Myers Squibb Company
USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE
Last updated:
Abstract:
The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.
Status:
Application
Type:
Utility
Filling date:
13 Jan 2022
Issue date:
28 Apr 2022